HealthQuill Clinical trials
The Food and Drug Administration has cleared the first at-home cervical cancer screening test in the US, according to a statement from Teal Health, its maker.
Health Medical Pharma

US approves first at-home cervical cancer screening from Teal Health

HQ Team May 12, 2025: The Food and Drug Administration has cleared the first at-home cervical cancer screening test in the US, according.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment. 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the treatment of generalised myasthenia gravis (gMG) — a rare disease that causes muscle weakness and affects daily activities like chewing, swallowing, speaking, and breathing.
Drugs Health Pharma

US regulator approves Johnson & Johnson’s immune disorder drug

HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.

Read More
British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal of the radiographic progression-free survival target in test patients.
Drugs Health Pharma

AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b

HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.

Read More
Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in the European Union of an oral drug for Duchenne muscular dystrophy in patients six years or older, who can walk.
Drugs Medical Pharma

Italfarmaco gets conditional marketing nod in EU for DMD drug

HQ Team April 27, 2025: Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in.

Read More
Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms in patients who are already on regular medication.
Drugs Health Pharma

Bristol Myers’ oral medication for schizophrenia fails to meet main goal

HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.
Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

Read More
Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in patients, two small trial studies show.
Drugs Health Research

Stem cell therapy revives hope for patients with Parkinson’s disease

HQ Team April 17, 2025: Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in.

Read More
Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.
Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

Read More
Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and Drug Administration, according to a statement.
Drugs Health Medical

Amgen gets US approval to treat immunoglobulin G4-related disease 

HQ Team April 4, 2025: Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and.

Read More